WIRE - Novel Treatments in Renal Cell Cancer

Summary

Evaluation of proof of mechanism with relation to ktrans and/or CD8 count when 3 different IMPs are given as monotherapy or as combination therapy. These would be administered in the "window of opportunity", prior to nephrectomy in surgically resectable renal cell cancer

Timeline

Start

2020-07-27

Primary completion

2025-11-30

Completion

2025-11-30

Publications

• Horvat-Menih I, McLean MA, Birchall J, Zamora Morales MJ, Wylot M, Ursprung S, Woitek R, Serrao E, Grimmer A, Latimer E, Khan AS, Priest AN, Gill AB, Kaggie JD, Graves MJ, Barrett T, Wason JM, Mossop H, Thomas M, Said S, Warren AY, Fife K, Eisen T, Matakidou A, Ince W, O'Carrigan B, Jones JO, Welsh SJ, Mitchell TJ, Armitage JN, Riddick AC, Stewart GD, Gallagher FA. Evaluating the metabolic effects of neoadjuvant treatment in clear cell renal cell carcinoma using hyperpolarized [1-13 C]pyruvate MRI. Abdom Radiol (NY). 2026 Jul;51(7):3557-3562. doi: 10.1007/s00261-025-05313-z. Epub 2025 Dec 10.
• Horvat-Menih I, Li H, Priest AN, Li S, Gill AB, Mendichovszky IA, Francis ST, Warren AY, O'Carrigan B, Welsh SJ, Jones JO, Riddick ACP, Armitage JN, Mitchell TJ, Stewart GD, Gallagher FA. High-resolution and highly accelerated MRI T2 mapping as a tool to characterise renal tumour subtypes and grades. Eur Radiol Exp. 2024 Jul 10;8(1):76. doi: 10.1186/s41747-024-00476-8.
• Ursprung S, Mossop H, Gallagher FA, Sala E, Skells R, Sipple JAN, Mitchell TJ, Chhabra A, Fife K, Matakidou A, Young G, Walker A, Thomas MG, Ortuzar MC, Sullivan M, Protheroe A, Oades G, Venugopal B, Warren AY, Stone J, Eisen T, Wason J, Welsh SJ, Stewart GD. The WIRE study a phase II, multi-arm, multi-centre, non-randomised window-of-opportunity clinical trial platform using a Bayesian adaptive design for proof-of-mechanism of novel treatment strategies in operable renal cell cancer - a study protocol. BMC Cancer. 2021 Nov 18;21(1):1238. doi: 10.1186/s12885-021-08965-4.

Drugs

Indications